Cargando…

The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal Study

BACKGROUND: The association of pro-inflammatory markers such as interleukin-6 (IL-6) and other biomarkers with severe coronavirus disease 2019 (COVID-19) is of increasing interest, however their kinetics, response to current COVID-related treatments, association with disease severity and comparison...

Descripción completa

Detalles Bibliográficos
Autores principales: Copaescu, Ana, James, Fiona, Mouhtouris, Effie, Vogrin, Sara, Smibert, Olivia C., Gordon, Claire L., Drewett, George, Holmes, Natasha E., Trubiano, Jason A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009986/
https://www.ncbi.nlm.nih.gov/pubmed/33815405
http://dx.doi.org/10.3389/fimmu.2021.646095
_version_ 1783672975342436352
author Copaescu, Ana
James, Fiona
Mouhtouris, Effie
Vogrin, Sara
Smibert, Olivia C.
Gordon, Claire L.
Drewett, George
Holmes, Natasha E.
Trubiano, Jason A.
author_facet Copaescu, Ana
James, Fiona
Mouhtouris, Effie
Vogrin, Sara
Smibert, Olivia C.
Gordon, Claire L.
Drewett, George
Holmes, Natasha E.
Trubiano, Jason A.
author_sort Copaescu, Ana
collection PubMed
description BACKGROUND: The association of pro-inflammatory markers such as interleukin-6 (IL-6) and other biomarkers with severe coronavirus disease 2019 (COVID-19) is of increasing interest, however their kinetics, response to current COVID-related treatments, association with disease severity and comparison with other disease states associated with potential cytokine storm (CS) such as Staphylococcus aureus bacteraemia (SAB) are ill-defined. METHODS: A cohort of 55 hospitalized SARS-CoV-2 positive patients was prospectively recruited – blood sampling was performed at baseline, post-treatment and hospital discharge. Serum IL-6, C-reactive protein (CRP) and other laboratory investigations were compared between treatment groups and across timepoints. Acute serum IL-6 and CRP levels were then compared to those with suspected COVID-19 (SCOVID) and age and sex matched patients with SAB and patients hospitalized for any non-infectious condition (NIC). RESULTS: IL-6 was elevated at admission in the SARS-CoV-2 cohort but at lower levels compared to matched SAB patients. Median (IQR) IL-6 at admission was 73.89 pg/mL (30.9, 126.39) in SARS-CoV-2 compared to 92.76 pg/mL (21.75, 246.55) in SAB (p=0.017); 12.50 pg/mL (3.06, 35.77) in patients with NIC; and 95.51 pg/mL (52.17, 756.67) in SCOVID. Median IL-6 and CRP levels decreased between admission and discharge timepoints. This reduction was amplified in patients treated with remdesivir and/or dexamethasone. CRP and bedside vital signs were the strongest predictors of COVID-19 severity. CONCLUSIONS: Knowledge of the kinetics of IL-6 did not offer enhanced predictive value for disease severity in COVID-19 over common investigations such as CRP and vital signs.
format Online
Article
Text
id pubmed-8009986
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80099862021-04-01 The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal Study Copaescu, Ana James, Fiona Mouhtouris, Effie Vogrin, Sara Smibert, Olivia C. Gordon, Claire L. Drewett, George Holmes, Natasha E. Trubiano, Jason A. Front Immunol Immunology BACKGROUND: The association of pro-inflammatory markers such as interleukin-6 (IL-6) and other biomarkers with severe coronavirus disease 2019 (COVID-19) is of increasing interest, however their kinetics, response to current COVID-related treatments, association with disease severity and comparison with other disease states associated with potential cytokine storm (CS) such as Staphylococcus aureus bacteraemia (SAB) are ill-defined. METHODS: A cohort of 55 hospitalized SARS-CoV-2 positive patients was prospectively recruited – blood sampling was performed at baseline, post-treatment and hospital discharge. Serum IL-6, C-reactive protein (CRP) and other laboratory investigations were compared between treatment groups and across timepoints. Acute serum IL-6 and CRP levels were then compared to those with suspected COVID-19 (SCOVID) and age and sex matched patients with SAB and patients hospitalized for any non-infectious condition (NIC). RESULTS: IL-6 was elevated at admission in the SARS-CoV-2 cohort but at lower levels compared to matched SAB patients. Median (IQR) IL-6 at admission was 73.89 pg/mL (30.9, 126.39) in SARS-CoV-2 compared to 92.76 pg/mL (21.75, 246.55) in SAB (p=0.017); 12.50 pg/mL (3.06, 35.77) in patients with NIC; and 95.51 pg/mL (52.17, 756.67) in SCOVID. Median IL-6 and CRP levels decreased between admission and discharge timepoints. This reduction was amplified in patients treated with remdesivir and/or dexamethasone. CRP and bedside vital signs were the strongest predictors of COVID-19 severity. CONCLUSIONS: Knowledge of the kinetics of IL-6 did not offer enhanced predictive value for disease severity in COVID-19 over common investigations such as CRP and vital signs. Frontiers Media S.A. 2021-03-17 /pmc/articles/PMC8009986/ /pubmed/33815405 http://dx.doi.org/10.3389/fimmu.2021.646095 Text en Copyright © 2021 Copaescu, James, Mouhtouris, Vogrin, Smibert, Gordon, Drewett, Holmes and Trubiano http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Copaescu, Ana
James, Fiona
Mouhtouris, Effie
Vogrin, Sara
Smibert, Olivia C.
Gordon, Claire L.
Drewett, George
Holmes, Natasha E.
Trubiano, Jason A.
The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal Study
title The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal Study
title_full The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal Study
title_fullStr The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal Study
title_full_unstemmed The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal Study
title_short The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapy—A Prospective Longitudinal Study
title_sort role of immunological and clinical biomarkers to predict clinical covid-19 severity and response to therapy—a prospective longitudinal study
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009986/
https://www.ncbi.nlm.nih.gov/pubmed/33815405
http://dx.doi.org/10.3389/fimmu.2021.646095
work_keys_str_mv AT copaescuana theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy
AT jamesfiona theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy
AT mouhtouriseffie theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy
AT vogrinsara theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy
AT smibertoliviac theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy
AT gordonclairel theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy
AT drewettgeorge theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy
AT holmesnatashae theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy
AT trubianojasona theroleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy
AT copaescuana roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy
AT jamesfiona roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy
AT mouhtouriseffie roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy
AT vogrinsara roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy
AT smibertoliviac roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy
AT gordonclairel roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy
AT drewettgeorge roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy
AT holmesnatashae roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy
AT trubianojasona roleofimmunologicalandclinicalbiomarkerstopredictclinicalcovid19severityandresponsetotherapyaprospectivelongitudinalstudy